TG Therapeutics (NASDAQ: TGTX)
TG Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
TG Therapeutics Company Info
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
News & Analysis
TG Therapeutics: Briumvi Revenue Soars
In the third quarter, the biopharma saw strong growth in sales of its sole approved treatment.
Why TG Therapeutics Stock Was Rocketing Higher This Week
The company raised guidance for sales of its drug for relapsing multiple sclerosis.
Why TG Therapeutics Stock Is Crushing It Today
The biopharmaceutical company's Q3 update was music to investors' ears.
Why TG Therapeutics Stock Is Crashing Today
The drugmaker delivered a couple of surprises in Q2.
3 Top Biotech Stocks Defying the Bear Market
All three companies have therapies with strong sales potential.
Why Shares of TG Therapeutics Soared on Tuesday
Early reports of strong sales for its recently approved multiple sclerosis drug gave the stock a jolt.
Why TG Therapeutics Stock Was a Solid Winner This Week
The company scored a giant victory on the regulatory front.
Why Shares of TG Therapeutics Climbed 59.9% This Week
The company got a big bump from the FDA.
Valuation
Earnings Transcripts
TG Therapeutics, inc (TGTX) Q3 2021 Earnings Call Transcript
TGTX earnings call for the period ending September 30, 2021.
TG Therapeutics, inc (TGTX) Q2 2021 Earnings Call Transcript
TGTX earnings call for the period ending June 30, 2021.
TG Therapeutics Inc (TGTX) Q1 2021 Earnings Call Transcript
TGTX earnings call for the period ending March 31, 2021.
TG Therapeutics Inc (TGTX) Q4 2020 Earnings Call Transcript
TGTX earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.